SG11201907211TA - Anti-pd-l1 antibody treatment of bladder cancer - Google Patents

Anti-pd-l1 antibody treatment of bladder cancer

Info

Publication number: SG11201907211TA
Authority: SG; Singapore
Prior art keywords: medimmune; llc; gaithersburg; way; bladder cancer
Prior art date: 2017-02-16

Application number

SG11201907211TA

Other languages

English (en)

Inventor

John Kurland

John Blake-Haskins

Magdalena Zajac

Marlon Rebelatto

Ashok Gupta

Tony Ho

Jill Walker

Xiaoping Jin

Shannon Morris

Robert Iannone

Li Shi

Mohammed Dar

yong Ben

Original Assignee

Medimmune Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-16

Filing date

2018-02-16

Publication date

2019-09-27

2018-02-16 Application filed by Medimmune Llc filed Critical Medimmune Llc

2019-09-27 Publication of SG11201907211TA publication Critical patent/SG11201907211TA/en

Links

208000007097 Urinary Bladder Neoplasms Diseases 0.000 title abstract 9
206010005003 Bladder cancer Diseases 0.000 title abstract 8
201000005112 urinary bladder cancer Diseases 0.000 title abstract 8
238000011282 treatment Methods 0.000 title abstract 5
238000000034 method Methods 0.000 abstract 3
238000002560 therapeutic procedure Methods 0.000 abstract 3
239000003795 chemical substances by application Substances 0.000 abstract 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
229950009791 durvalumab Drugs 0.000 abstract 1
238000009093 first-line therapy Methods 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000002955 immunomodulating agent Substances 0.000 abstract 1
230000008520 organization Effects 0.000 abstract 1
229910052697 platinum Inorganic materials 0.000 abstract 1
206010044412 transitional cell carcinoma Diseases 0.000 abstract 1
238000011269 treatment regimen Methods 0.000 abstract 1
229950007217 tremelimumab Drugs 0.000 abstract 1
208000023747 urothelial carcinoma Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Dermatology (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SG11201907211TA 2017-02-16 2018-02-16 Anti-pd-l1 antibody treatment of bladder cancer SG11201907211TA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201762459700P	2017-02-16	2017-02-16
PCT/US2018/018513 WO2018152415A1 (en)	2017-02-16	2018-02-16	Anti-pd-l1 antibody treatment of bladder cancer

Publications (1)

Publication Number	Publication Date
SG11201907211TA true SG11201907211TA (en)	2019-09-27

Family

ID=63169615

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201907211TA SG11201907211TA (en)	2017-02-16	2018-02-16	Anti-pd-l1 antibody treatment of bladder cancer

Country Status (12)

Country	Link
US (2)	US20190359715A1 (ru)
EP (1)	EP3582805A4 (ru)
JP (2)	JP2020507596A (ru)
KR (2)	KR20230145547A (ru)
CN (2)	CN110290803A (ru)
AU (1)	AU2018221822A1 (ru)
CA (1)	CA3052652A1 (ru)
EA (1)	EA201991870A1 (ru)
IL (2)	IL302777A (ru)
MA (1)	MA47509A (ru)
SG (1)	SG11201907211TA (ru)
WO (1)	WO2018152415A1 (ru)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20210149870A (ko) *	2014-05-13	2021-12-09	메디뮨 리미티드	비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
US11168144B2 (en)	2017-06-01	2021-11-09	Cytomx Therapeutics, Inc.	Activatable anti-PDL1 antibodies, and methods of use thereof
EP4153783A1 (en) *	2020-05-21	2023-03-29	Astrazeneca AB	Tumor mutational burden associated with sensitivity to immunotherapy in locally advanced or metastatic urothelial carcinoma

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7947261B2 (en) *	2003-05-23	2011-05-24	Nektar Therapeutics	Conjugates formed from polymer derivatives having particular atom arrangements
KR20210149870A (ko) *	2014-05-13	2021-12-09	메디뮨 리미티드	비-소세포 폐암을 치료하기 위한 항-ｂ7-ｈ1 및 항-ｃｔｌａ-4 항체
ES2789500T5 (es) *	2015-05-29	2023-09-20	Hoffmann La Roche	Procedimientos terapéuticos y de diagnóstico para el cáncer
WO2017100541A1 (en) *	2015-12-10	2017-06-15	Gerd Binnig	Methods for treatment and selection of patients responsive to immune mediated cancer therapy
MX2018012651A (es) *	2016-04-25	2019-01-30	Medimmune Llc	Composiciones que comprenden coformulacion de anticuerpos anti-ligando-1 de muerte celular programada (pd-l1) y anti-antigeno-4 asociado a linfocitos t citotoxicos (ctla-4).

2018
- 2018-02-16 CN CN201880011428.2A patent/CN110290803A/zh active Pending
- 2018-02-16 SG SG11201907211TA patent/SG11201907211TA/en unknown
- 2018-02-16 JP JP2019543851A patent/JP2020507596A/ja active Pending
- 2018-02-16 CN CN202410133870.XA patent/CN118001389A/zh active Pending
- 2018-02-16 IL IL302777A patent/IL302777A/en unknown
- 2018-02-16 AU AU2018221822A patent/AU2018221822A1/en active Pending
- 2018-02-16 EA EA201991870A patent/EA201991870A1/ru unknown
- 2018-02-16 KR KR1020237034594A patent/KR20230145547A/ko not_active Application Discontinuation
- 2018-02-16 MA MA047509A patent/MA47509A/fr unknown
- 2018-02-16 US US16/486,222 patent/US20190359715A1/en not_active Abandoned
- 2018-02-16 EP EP18753778.2A patent/EP3582805A4/en active Pending
- 2018-02-16 CA CA3052652A patent/CA3052652A1/en active Pending
- 2018-02-16 KR KR1020197026803A patent/KR20190117014A/ko not_active Application Discontinuation
- 2018-02-16 WO PCT/US2018/018513 patent/WO2018152415A1/en unknown
2019
- 2019-08-04 IL IL268460A patent/IL268460A/en unknown
2022
- 2022-04-14 US US17/720,903 patent/US20220332828A1/en active Pending
2023
- 2023-12-22 JP JP2023216425A patent/JP2024038034A/ja active Pending

Also Published As

Publication number	Publication date
IL268460A (en)	2019-09-26
JP2020507596A (ja)	2020-03-12
EA201991870A1 (ru)	2020-02-12
KR20190117014A (ko)	2019-10-15
KR20230145547A (ko)	2023-10-17
CA3052652A1 (en)	2018-08-23
IL302777A (en)	2023-07-01
CN110290803A (zh)	2019-09-27
JP2024038034A (ja)	2024-03-19
US20220332828A1 (en)	2022-10-20
MA47509A (fr)	2019-12-25
EP3582805A4 (en)	2021-03-10
AU2018221822A1 (en)	2019-09-26
CN118001389A (zh)	2024-05-10
US20190359715A1 (en)	2019-11-28
EP3582805A1 (en)	2019-12-25
WO2018152415A1 (en)	2018-08-23

Publication	Publication Date	Title
SG11201900885VA (en)	2019-02-27	Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201804839WA (en)	2018-07-30	Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
SG11201803956UA (en)	2018-06-28	Anti-dr5 antibodies and methods of use thereof
SG11201809089QA (en)	2018-11-29	Bispecific binding proteins and uses thereof
SG11201900677SA (en)	2019-02-27	Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201909572QA (en)	2019-11-28	Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
SG11201807176XA (en)	2018-09-27	TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201906297QA (en)	2019-10-30	Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201900344YA (en)	2019-02-27	Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
SG11201810883TA (en)	2019-01-30	Combination therapy
SG11201903454VA (en)	2019-05-30	Immunologically discernible cell surface variants for use in cell therapy
SG11201907891XA (en)	2019-09-27	Combination therapy for the treatment or prevention of tumours
SG11201806340YA (en)	2018-09-27	Zika virus vaccine
SG11201907753TA (en)	2019-09-27	Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201908391XA (en)	2019-10-30	Methods for modulating an immune response
SG11201810023QA (en)	2018-12-28	Anti-tim-3 antibodies and methods of use thereof
SG11201906192SA (en)	2019-08-27	Methods of treating cancer with anti-pd-1 antibodies
SG11201808314QA (en)	2018-10-30	Compositions and methods for the treatment of wounds, disorders, and diseases of the skin
SG11201806251WA (en)	2018-08-30	Methods for treating er+, her2-, hrg+ breast cancer using combination therapies comprising an anti-erbb3 antibody
SG11201907211TA (en)	2019-09-27	Anti-pd-l1 antibody treatment of bladder cancer
SG11201906386XA (en)	2019-08-27	Combination therapy involving diaryl macrocyclic compounds
SG11201900745VA (en)	2019-02-27	Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201901961SA (en)	2019-04-29	Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
SG11201804263PA (en)	2018-06-28	Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
SG11201901762WA (en)	2019-03-28	Methods and composition for the prediction of the activity of enzastaurin